GlassScriptPhysician profile
Michelle D Johnson
NPI 1083015424
$1,908.10
in general payments reported to CMS, 2019-2025
24 companies · $249 in 2025
The $249 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $368 · 2022: $520 · 2023: $508 · 2024: $263 · 2025: $249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $879 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $879.10 |
| Education | $140.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $182.37 | 2022-2023 | Rayaldee |
| Insulet Corporation | $144.02 | 2025 | Omnipod |
| Horizon Therapeutics Plc | $133.58 | 2021-2023 | Tepezza |
| Amgen INC. | $131.81 | 2022-2024 | Tavneos |
| Tandem Diabetes Care, INC. | $123.67 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $115.86 | 2021-2024 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $113.56 | 2021-2024 | |
| Alkermes, INC. | $106.80 | 2023 | Lybalvi |
| Astrazeneca Pharmaceuticals LP | $98.28 | 2021-2023 | Evusheld |
| Dexcom, INC. | $91.44 | 2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $83.34 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.97 | 2021-2024 | Jardiance, Synjardy |
| Novo Nordisk INC | $68.35 | 2021-2024 | Wegovy |
| Janssen Biotech, INC. | $63.04 | 2022 | |
| Mallinckrodt Hospital Products INC. | $57.68 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $53.14 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $44.24 | 2021 | |
| Ucb, INC. | $43.59 | 2021-2022 | |
| Medtronic, INC. | $43.24 | 2021-2023 | Intellis Adaptivestim |
| Lilly USA, LLC | $41.16 | 2021-2024 | Zepbound, Mounjaro |
| Vyaire Medical, INC. | $39.92 | 2022 | |
| Genzyme Corporation | $21.95 | 2021 | |
| Abbvie INC. | $18.73 | 2021 | |
| Travere Therapeutics, INC. | $13.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.